This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (348)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Cardiovascular System  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

The IDEAL Study: A Randomized Controlled Trial

Terje R. Pedersen, MD, PhD; Ole Faergeman, MD, DMSc; John J. P. Kastelein, MD, PhD; Anders G. Olsson, MD, PhD; Matti J. Tikkanen, MD, PhD; Ingar Holme, PhD; Mogens Lytken Larsen, MD, DMSc; Fredrik S. Bendiksen, MD; Christina Lindahl, MD; Michael Szarek, MS; John Tsai, MD; for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group

JAMA. 2005;294:2437-2445.

Context  Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable coronary artery disease.

Objective  To compare the effects of 2 strategies of lipid lowering on the risk of cardiovascular disease among patients with a previous myocardial infarction (MI).

Design, Setting, and Participants  The IDEAL study, a prospective, randomized, open-label, blinded end-point evaluation trial conducted at 190 ambulatory cardiology care and specialist practices in northern Europe between March 1999 and March 2005 with a median follow-up of 4.8 years, which enrolled 8888 patients aged 80 years or younger with a history of acute MI.

Interventions  Patients were randomly assigned to receive a high dose of atorvastatin (80 mg/d; n = 4439), or usual-dose simvastatin (20 mg/d; n = 4449).

Main Outcome Measure  Occurrence of a major coronary event, defined as coronary death, confirmed nonfatal acute MI, or cardiac arrest with resuscitation.

Results  During treatment, mean LDL-C levels were 104 (SE, 0.3) mg/dL in the simvastatin group and 81 (SE, 0.3) mg/dL in the atorvastatin group. A major coronary event occurred in 463 simvastatin patients (10.4%) and in 411 atorvastatin patients (9.3%) (hazard ratio [HR], 0.89; 95% CI, 0.78-1.01; P = .07). Nonfatal acute MI occurred in 321 (7.2%) and 267 (6.0%) in the 2 groups (HR, 0.83; 95% CI, 0.71-0.98; P = .02), but no differences were seen in the 2 other components of the primary end point. Major cardiovascular events occurred in 608 and 533 in the 2 groups, respectively (HR, 0.87; 95% CI, 0.77-0.98; P = .02). Occurrence of any coronary event was reported in 1059 simvastatin and 898 atorvastatin patients (HR, 0.84; 95% CI, 0.76-0.91; P<.001). Noncardiovascular death occurred in 156 (3.5%) and 143 (3.2%) in the 2 groups (HR, 0.92; 95% CI, 0.73-1.15; P = .47). Death from any cause occurred in 374 (8.4%) in the simvastatin group and 366 (8.2%) in the atorvastatin group (HR, 0.98; 95% CI, 0.85-1.13; P = .81). Patients in the atorvastatin group had higher rates of drug discontinuation due to nonserious adverse events; transaminase elevation resulted in 43 (1.0%) vs 5 (0.1%) withdrawals (P<.001). Serious myopathy and rhabdomyolysis were rare in both groups.

Conclusions  In this study of patients with previous MI, intensive lowering of LDL-C did not result in a significant reduction in the primary outcome of major coronary events, but did reduce the risk of other composite secondary end points and nonfatal acute MI. There were no differences in cardiovascular or all-cause mortality. Patients with MI may benefit from intensive lowering of LDL-C without an increase in noncardiovascular mortality or other serious adverse reactions.

Trial Registration  ClinicalTrials.gov Identifier: NCT00159835.

Author Affiliations: Centre for Preventive Medicine, Ullevål University Hospital, Oslo, Norway (Drs Pedersen and Holme); Department of Medicine–Cardiology A, Århus University Hospital, Århus, Denmark (Drs Faergeman and Larsen); Academic Hospital Amsterdam, Amsterdam, the Netherlands (Dr Kastelein); Department of Internal Medicine, University Hospital, Linköping, Sweden (Dr Olsson); Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (Dr Tikkanen); Pfizer Sweden, Täby, Sweden (Dr Lindahl); and Pfizer Inc, New York, NY (Mr Szarek and Dr Tsai). Dr Bendiksen is in private practice in Hamar, Norway.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

High-Dose Statins and the IDEAL Study
Uffe Ravnskov, Paul J. Rosch, and Morley C. Sutter
JAMA. 2006;295(21):2476.
EXTRACT | FULL TEXT  

High-Dose Statins and the IDEAL Study
William E. Cayley, Jr
JAMA. 2006;295(21):2476.
EXTRACT | FULL TEXT  

High-Dose Statins and the IDEAL Study
Hean T. Ong and Jim Seng Cheah
JAMA. 2006;295(21):2476-2477.
EXTRACT | FULL TEXT  

High-Dose Statins and the IDEAL Study
Paul S. Chan, Brahmajee K. Nallamothu, and Rodney A. Hayward
JAMA. 2006;295(21):2477.
EXTRACT | FULL TEXT  

High-Dose Statins and the IDEAL Study
Samuel J. Mann
JAMA. 2006;295(21):2477-2478.
EXTRACT | FULL TEXT  

High-Dose Statins and the IDEAL Study—Reply
Terje R. Pedersen, Ole Faergeman, John J. P. Kastelein, Anders G. Olsson, Matti J. Tikkanen, Ingar Holme, Mogens Lytken Larsen, and Fredrik S. Bendiksen
JAMA. 2006;295(21):2478-2479.
EXTRACT | FULL TEXT  

RELATED ARTICLE

The IDEAL Cholesterol: Lower Is Better
Christopher P. Cannon
JAMA. 2005;294(19):2492-2494.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease
Hayward et al.
ANN INTERN MED 2010;152:69-77.
ABSTRACT | FULL TEXT  

Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy Insights From the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Trial.
Tikkanen et al.
J Am Coll Cardiol 2009;54:2353-2357.
ABSTRACT | FULL TEXT  

Cardiovascular and Economic Outcomes After Initiation of Lipid-Lowering Therapy With Atorvastatin vs Simvastatin in an Employed Population
Simpson et al.
Mayo Clin Proc. 2009;84:1065-1072.
ABSTRACT | FULL TEXT  

Does Simvastatin Cause More Myotoxicity Compared with Other Statins?
Backes et al.
The Annals of Pharmacotherapy 2009;43:2012-2020.
ABSTRACT | FULL TEXT  

Statins in Acute Coronary Syndromes: Do the Guideline Recommendations Match the Evidence?
Morrissey et al.
J Am Coll Cardiol 2009;54:1425-1433.
ABSTRACT | FULL TEXT  

Early Statin Therapy in Acute Coronary Syndromes: The Successful Cycle of Evidence, Guidelines, and Implementation
Waters and Ku
J Am Coll Cardiol 2009;54:1434-1437.
ABSTRACT | FULL TEXT  

Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach
O'Keefe et al.
Mayo Clin Proc. 2009;84:741-757.
ABSTRACT | FULL TEXT  

Effect of high-intensity statin treatment in rheumatoid arthritis: a case with possible coronary atheroma regression and progression of rheumatoid valve degeneration
Semb et al.
BMJ Case Reports 2009;2009:bcr0820080717-bcr0820080717.
ABSTRACT | FULL TEXT  

PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study
Schlitt et al.
J. Lipid Res. 2009;50:723-729.
ABSTRACT | FULL TEXT  

Macrovascular Complications of Diabetes Mellitus
Nuzum and Merz
Journal of Pharmacy Practice 2009;22:135-148.
ABSTRACT  

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia
Minhas et al.
Heart 2009;95:584-587.
FULL TEXT  

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease
Karalis
Mayo Clin Proc. 2009;84:345-352.
ABSTRACT | FULL TEXT  

Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death
Scirica et al.
Clin. Chem. 2009;55:265-273.
ABSTRACT | FULL TEXT  

Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.
Robinson et al.
J Am Coll Cardiol 2009;53:316-322.
ABSTRACT | FULL TEXT  

Association Between Statin Use and Risk for Keratinocyte Carcinoma in the Veterans Affairs Topical Tretinoin Chemoprevention Trial
Dore et al.
ANN INTERN MED 2009;150:9-18.
ABSTRACT | FULL TEXT  

JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
SHISHEHBOR and HAZEN
Cleveland Clinic Journal of Medicine 2009;76:37-44.
ABSTRACT | FULL TEXT  

The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study
Sathyapalan et al.
J. Clin. Endocrinol. Metab. 2009;94:103-108.
ABSTRACT | FULL TEXT  

Statins: established indications and controversial subgroups
Jukema and Bergheanu
Heart 2008;94:1656-1662.
FULL TEXT  

Primary Prevention and Statins: Is It Just About Going to Class?
Krasuski
Mayo Clin Proc. 2008;83:1313-1315.
FULL TEXT  

Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated
Jacobson et al.
Mayo Clin Proc. 2008;83:1316-1325.
ABSTRACT | FULL TEXT  

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy and Yellon
Postgrad. Med. J. 2008;84:590-598.
ABSTRACT | FULL TEXT  

Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?
Talelli and Greenwood
Ther Adv Cardiovasc Dis 2008;2:387-405.
ABSTRACT  

Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline
Rosenzweig et al.
J. Clin. Endocrinol. Metab. 2008;93:3671-3689.
ABSTRACT | FULL TEXT  

Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Analysis
Giraldez et al.
J Am Coll Cardiol 2008;52:914-920.
ABSTRACT | FULL TEXT  

Aggressive Therapy Is Not Always the Best Therapy
Bruschke and Jukema
J Am Coll Cardiol 2008;52:921-923.
FULL TEXT  

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)
Newman et al.
Diabetes and Vascular Disease Research 2008;5:177-183.
ABSTRACT  

SLCO1B1 Variants and Statin-Induced Myopathy -- A Genomewide Study
The SEARCH Collaborative Group
NEJM 2008;359:789-799.
ABSTRACT | FULL TEXT  

The Effects of Medications on Myocardial Perfusion
Zoghbi et al.
J Am Coll Cardiol 2008;52:401-416.
ABSTRACT | FULL TEXT  

Statins and Heart Failure
Filippatos and Mikhailidis
ANGIOLOGY 2008;59:58S-61S.
ABSTRACT  

Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease
Settergren et al.
Eur Heart J 2008;29:1753-1760.
ABSTRACT | FULL TEXT  

Do People With Diabetes Need Statins?
White
The Diabetes Educator 2008;34:664-673.
ABSTRACT | FULL TEXT  

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
Kastelein et al.
Circulation 2008;117:3002-3009.
ABSTRACT | FULL TEXT  

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy and Yellon
Heart 2008;94:706-714.
ABSTRACT | FULL TEXT  

Cholesterol Synthesis Inhibition Elicits an Integrated Molecular Response in Human Livers Including Decreased ACAT2
Parini et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:1200-1206.
ABSTRACT | FULL TEXT  

Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery
Shah et al.
J Am Coll Cardiol 2008;51:1938-1943.
ABSTRACT | FULL TEXT  

Estrogen Receptor-Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users
Kumar et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1028-1033.
ABSTRACT | FULL TEXT  

Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
J Am Coll Cardiol 2008;51:1512-1524.
FULL TEXT  

Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard et al.
JAMA 2008;299:1678-1689.
ABSTRACT | FULL TEXT  

Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein et al.
NEJM 2008;358:1431-1443.
ABSTRACT | FULL TEXT  

Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
Diabetes Care 2008;31:811-822.
FULL TEXT  

Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study
Wenger et al.
Heart 2008;94:434-439.
ABSTRACT | FULL TEXT  

Achieving Vascular Risk Factor Targets: A Survey of a London General Practice
Levine et al.
ANGIOLOGY 2008;59:36-46.
ABSTRACT  

The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Josan et al.
CMAJ 2008;178:576-584.
ABSTRACT | FULL TEXT  

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
van der Steeg et al.
J Am Coll Cardiol 2008;51:634-642.
ABSTRACT | FULL TEXT  

Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko and King
Circulation 2008;117:560-568.
FULL TEXT  

Thyroid mimetic as an option for lowering low-density lipoprotein
Grundy
Proc. Natl. Acad. Sci. USA 2008;105:409-410.
FULL TEXT  

LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?
Nesto
Clin. Diabetes 2008;26:8-13.
ABSTRACT | FULL TEXT  

Low low-density lipoprotein cholesterol and cancer risk.
Strandberg
J Am Coll Cardiol 2008;51:91-92.
FULL TEXT  

Impact of Patient and Plan Design Factors on Switching to Preferred Statin Therapy
Cox et al.
The Annals of Pharmacotherapy 2007;41:1946-1953.
ABSTRACT | FULL TEXT  

Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease: The Treating to New Targets (TNT) Study
Shepherd et al.
CJASN 2007;2:1131-1139.
ABSTRACT | FULL TEXT  

Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease
Mudd et al.
J Am Coll Cardiol 2007;50:1735-1741.
ABSTRACT | FULL TEXT  

Biases in the Identification of Risk Factor Thresholds and J-Curves
Marschner et al.
Am J Epidemiol 2007;166:824-831.
ABSTRACT | FULL TEXT  

Statins and Children: Whom Do We Treat and When?
Stein
Circulation 2007;116:594-595.
FULL TEXT  

Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival
Leeper et al.
Circulation 2007;116:613-618.
ABSTRACT | FULL TEXT  

Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Afilalo et al.
Heart 2007;93:914-921.
ABSTRACT | FULL TEXT  

Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice
Choudhry et al.
Heart 2007;93:945-951.
ABSTRACT | FULL TEXT  

Atorvastatin Treatment and Vaccination Efficacy
Packard et al.
J Clin Pharmacol 2007;47:1022-1027.
FULL TEXT  

Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
Alsheikh-Ali et al.
J Am Coll Cardiol 2007;50:409-418.
ABSTRACT | FULL TEXT  

Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease
Wenger et al.
ANN INTERN MED 2007;147:1-9.
ABSTRACT | FULL TEXT  

Do statins have an antiarrhythmic activity?
Kostapanos et al.
Cardiovasc Res 2007;75:10-20.
ABSTRACT | FULL TEXT  

Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
Kaul
Eur Heart J 2007;0:ehm168v1-2.
FULL TEXT  

Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
Lindgren et al.
Eur Heart J 2007;28:1448-1453.
ABSTRACT | FULL TEXT  

Statins: Targeting Inflammation by Lowering Low-Density Lipoprotein?
Tuzcu and Nicholls
J Am Coll Cardiol 2007;49:2010-2012.
FULL TEXT  

Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease
Chan et al.
Circulation 2007;115:2398-2409.
ABSTRACT | FULL TEXT  

Which statin, what dose?
DTB 2007;45:33-37.
ABSTRACT | FULL TEXT  

Update on Dyslipidemia
Garg and Simha
J. Clin. Endocrinol. Metab. 2007;92:1581-1589.
ABSTRACT | FULL TEXT  

Suppressive Effects of Statins on Acute Promyelocytic Leukemia Cells
Sassano et al.
Cancer Res. 2007;67:4524-4532.
ABSTRACT | FULL TEXT  

Safety of Aggressive Lipid Management
Davidson and Robinson
J Am Coll Cardiol 2007;49:1753-1762.
ABSTRACT | FULL TEXT  

Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population
Song et al.
Am J Health Syst Pharm 2007;64:767-772.
ABSTRACT | FULL TEXT  

A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel et al.
Eur Heart J 2007;28:664-672.
ABSTRACT | FULL TEXT  

Lipid-Lowering Therapy and Outcomes in Heart Failure
Ray et al.
J CARDIOVASC PHARMACOL THER 2007;12:27-35.
ABSTRACT  

Coronary Heart Disease in Patients With Diabetes: Part I: Recent Advances in Prevention and Noninvasive Management
Berry et al.
J Am Coll Cardiol 2007;49:631-642.
ABSTRACT | FULL TEXT  

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
Nicholls et al.
JAMA 2007;297:499-508.
ABSTRACT | FULL TEXT  

The effect of intensive lipid lowering on coronary atheroma and clinical outcome
Houslay et al.
Heart 2007;93:149-151.
ABSTRACT | FULL TEXT  

Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?
Robinson et al.
Stroke 2007;38:441-450.
ABSTRACT | FULL TEXT  

Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study
Penning-van Beest et al.
Eur Heart J 2007;28:154-159.
ABSTRACT | FULL TEXT  

Rational therapy of mixed dyslipidaemia in a patient with diabetes
Reasner
British Journal of Diabetes & Vascular Disease 2007;7:25-30.
ABSTRACT  

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease)
Dzau et al.
Circulation 2006;114:2850-2870.
FULL TEXT  

Fibrates after the FIELD study: some answers, more questions
Wierzbicki
Diabetes and Vascular Disease Research 2006;3:166-171.
ABSTRACT  

Cholesteryl Ester Transfer Protein Inhibition: The Next Frontier in Combating Coronary Artery Disease?
Milani and Lavie
J Am Coll Cardiol 2006;48:1791-1792.
FULL TEXT  

Analysis of Efficacy and Safety in Patients Aged 65-75 Years at Randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
Neil et al.
Diabetes Care 2006;29:2378-2384.
ABSTRACT | FULL TEXT  

Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.
Hayward et al.
ANN INTERN MED 2006;145:520-530.
ABSTRACT | FULL TEXT  

The gap between theory and practice: what do the trials tell us?
Pedersen
Eur Heart J Suppl 2006;8:F10-F16.
ABSTRACT | FULL TEXT  

Reducing risk by raising HDL-cholesterol: the evidence
Drexel
Eur Heart J Suppl 2006;8:F23-F29.
ABSTRACT | FULL TEXT  

Niaspan(R) in the management of dyslipidaemia: the evidence
Brown
Eur Heart J Suppl 2006;8:F60-F67.
ABSTRACT | FULL TEXT  

Achieving the therapeutic benefits of Niaspan(R) in daily practice
Reasner
Eur Heart J Suppl 2006;8:F68-F73.
ABSTRACT | FULL TEXT  

Evidence to support aggressive management of HDL-cholesterol: implications of recent trials
Taylor
Eur Heart J Suppl 2006;8:F74-F80.
ABSTRACT | FULL TEXT